Literature DB >> 7870982

Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero.

J R Martin1, P Schoch, F Jenck, J L Moreau, W E Haefely.   

Abstract

Several benzodiazepine receptor ligands were pharmacologically characterized in a battery of functional tests after oral administration in mice, rats, and monkeys. Previous experiments have consistently demonstrated that diazepam exhibits high intrinsic efficacy, bretazenil exhibits intermediate intrinsic efficacy, Ro 42-8773 and Ro 41-7812 both show low intrinsic efficacy, and flumazenil exhibits virtually zero intrinsic efficacy. In the test battery used here it appears that nearly full intrinsic efficacy is required for clear anterograde amnesia or rotarod impairment. In contrast, full protection in the pentetetrazol test was achieved with intermediate-to-high intrinsic efficacy and nearly full protection with lower intrinsic efficacy. In the audiogenic seizure test full anticonvulsant effects were produced with intrinsic efficacy ranging from low to high. Clear inhibition of punished operant responding was observed for all test compounds except for Ro 41-7812 and flumazenil, which exhibit the lowest intrinsic efficacies. All of the test compounds enhanced palatable food consumption, with even those having low intrinsic efficacy producing maximum effects approximating that of diazepam. By additionally taking into consideration the degree of receptor occupancy required to obtain pharmacological activity in each of the tests in this battery it is possible to order the compounds with respect to intrinsic efficacy: diazepam > bretazenil > Ro 42-8773 > Ro 41-7812 > flumazenil. The latter four compounds all exhibited a maximum antagonistic activity in tests involving reversal of meclonazepam- or flunitrazepam-induced central nervous system depression. Thus, using these tests appears to permit the accurate ordinal classification of benzodiazepine receptor ligands for intrinsic efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870982     DOI: 10.1007/bf02253530

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

Review 1.  Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.

Authors:  W Haefely; M Facklam; P Schoch; J R Martin; E P Bonetti; J L Moreau; F Jenck; J G Richards
Journal:  Adv Biochem Psychopharmacol       Date:  1992

2.  Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies.

Authors:  M Facklam; P Schoch; E P Bonetti; F Jenck; J R Martin; J L Moreau; W E Haefely
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

3.  Physical dependence induced in DBA/2J mice by benzodiazepine receptor full agonists, but not by the partial agonist Ro 16-6028.

Authors:  J L Moreau; F Jenck; L Pieri; P Schoch; J R Martin; W E Haefely
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

Review 4.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor.

Authors:  J R Martin; L Pieri; E P Bonetti; R Schaffner; W P Burkard; R Cumin; W E Haefely
Journal:  Pharmacopsychiatry       Date:  1988-11       Impact factor: 5.788

6.  Benzodiazepine receptor binding in vivo with [3H]-Ro 15-1788.

Authors:  N E Goeders; M J Kuhar
Journal:  Life Sci       Date:  1985-07-29       Impact factor: 5.037

7.  Feasibility of reversing benzodiazepine tolerance with flumazenil.

Authors:  I Savic; L Widén; S Stone-Elander
Journal:  Lancet       Date:  1991-01-19       Impact factor: 79.321

8.  Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder.

Authors:  S W Woods; D S Charney; J M Silver; J H Krystal; G R Heninger
Journal:  Psychiatry Res       Date:  1991-02       Impact factor: 3.222

Review 9.  Novel anxiolytics that act as partial agonists at benzodiazepine receptors.

Authors:  W Haefely; J R Martin; P Schoch
Journal:  Trends Pharmacol Sci       Date:  1990-11       Impact factor: 14.819

10.  RO 16-6028, a benzodiazepine receptor partial agonist, does not exhibit anticonvulsant tolerance in mice.

Authors:  J R Haigh; M Feely
Journal:  Eur J Pharmacol       Date:  1988-03-01       Impact factor: 4.432

  10 in total
  10 in total

1.  Anti-conflict effects of benzodiazepines in rhesus monkeys: relationship with therapeutic doses in humans and role of GABAA receptors.

Authors:  James K Rowlett; Snjezana Lelas; Walter Tornatzky; Stephanie C Licata
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

2.  The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.

Authors:  G Griebel; D J Sanger; G Perrault
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

3.  Benzodiazepine (omega) receptor partial agonists and the acquisition of conditioned fear in mice.

Authors:  D J Sanger; D Joly; G Perrault
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

4.  Benzodiazepine-GABAA receptor complex ligands in two models of anxiety.

Authors:  M Nazar; M Jessa; A Płaźnik
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  An operant determination of the behavioral mechanism of benzodiazepine enhancement of food intake.

Authors:  E O'Hare; E-M Kim; K J Tierney
Journal:  Psychopharmacology (Berl)       Date:  2006-05-21       Impact factor: 4.530

6.  A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat.

Authors:  F Jenck; J Wichmann; F M Dautzenberg; J L Moreau; A M Ouagazzal; J R Martin; K Lundstrom; A M Cesura; S M Poli; S Roever; S Kolczewski; G Adam; G Kilpatrick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Self-administration of bretazenil under progressive-ratio schedules: behavioral economic analysis of the role intrinsic efficacy plays in the reinforcing effects of benzodiazepines.

Authors:  Stephanie C Licata; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2010-08-30       Impact factor: 4.492

8.  Ojeok-san ameliorates visceral and somatic nociception in a mouse model of colitis induced colorectal cancer.

Authors:  Patrice Cunningham; Aman Sumal; Emma Patton; Henry Helms; Matthew T Noneman; Gustavo Martinez-Muñiz; Jackie E Bader; Ioulia Chatzistamou; Ahmed Aladhami; Christian Unger; Reilly T Enos; Hyeun Kyoo Shin; Kandy T Velázquez
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

9.  Behavioral effects of flumazenil in the social conflict test in mice.

Authors:  L Uhlírová; M Sustková-Fiserová; M Krsiak
Journal:  Psychopharmacology (Berl)       Date:  2003-09-05       Impact factor: 4.530

10.  Restoration of KCC2 Membrane Localization in Striatal Dopamine D2 Receptor-Expressing Medium Spiny Neurons Rescues Locomotor Deficits in HIV Tat-Transgenic Mice.

Authors:  Aaron J Barbour; Sara R Nass; Yun K Hahn; Kurt F Hauser; Pamela E Knapp
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.